Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice.

ABSTRACT:

Background

The recent development of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have expanded the possibilities of pharmacological treatment for patients with juvenile idiopathic arthritis (JIA). The objective of this study is to evaluate trends in initial prescriptions for these targeted therapies in patients aged 0-18 years with non-systemic JIA in clinical practice. We also identified the approval dates and key regulatory changes for each medication.

Methods

A retrospective cohort study was conducted using prescription records from the Wilhelmina Children's Hospital, the largest pediatric rheumatology center in the Netherlands, analyzing data from January 2012 to December 2023. The market introduction of targeted th

SUBMITTER: Lamers HC 

PROVIDER: S-EPMC12750840 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature